Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-20

Study Completion Date

2022-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is evaluating if rivaroxaban 2.5 mg BID and aspirin 100 mg OD compared to aspirin alone improves on intermittent claudication distance in PAD patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD

NCT04305028

Peripheral Arterial Disease

UNKNOWN

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

NCT01776424

Prevention & Control

COMPLETED PHASE3

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

NCT03718429

Coronary Artery Disease Peripheral Arterial Disease Atrial Fibrillation

COMPLETED PHASE4

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862

Peripheral Arterial Disease

ACTIVE_NOT_RECRUITING PHASE4

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

NCT02833948

Aortic Valve Stenosis Cardiovascular Diseases Heart Valve Diseases +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: The COMPASS trial demonstrated that in patients with peripheral arterial disease the combination of rivaroxaban and aspirin compared with aspirin reduces the risk of major adverse limb events, but it is not known whether this combination can also improve symptoms in patients with intermittent claudication. The primary objective of this study is to evaluate the effect of the combination on intermittent claudication distance.

Study design: Eighty-eight patients with intermittent claudication will be randomized to receive rivaroxaban 2,5 mg twice daily plus aspirin 100 mg once daily or aspirin 100 mg once daily for 24 weeks. The primary outcome is the change in claudication distance from baseline to 24 hours as measured by 6 minutes walking test and treadmill test. The main safety outcome is the incidence of major bleeding according to ISTH criteria.

Summary: The COMPASS CLAUDICATION trial will provide high-quality evidence regarding the effect of the combination of rivaroxaban and aspirin on claudication distance in patients with peripheral arterial disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease Intermittent Claudication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

2 arms, active comparator (vascular dose) versus aspirin alone

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

open label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vascular dose

Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months

Group Type EXPERIMENTAL

Rivaroxaban 2.5 Mg Oral Tablet

Intervention Type DRUG

oral anticoagulants plus antiplatelet agent

Aspirin

Aspirin 100 mg OD for 6 months

Group Type ACTIVE_COMPARATOR

Rivaroxaban 2.5 Mg Oral Tablet

Intervention Type DRUG

oral anticoagulants plus antiplatelet agent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban 2.5 Mg Oral Tablet

oral anticoagulants plus antiplatelet agent

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aspirin 100 Mg oral Tablet

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with symptomatic PAD who signed the informed consent form (ICF) with:

1. Ankle-brachial index (ABI) \< 0. 85 in at least one member, and
2. ACD \< 500 meters
3. age \> 18 years
4. No history of lower-limbs arterial bypass surgery or angioplasties in the last year
5. walking ability limited by the symptom of claudication and
6. ability to complete a treadmill test

Exclusion Criteria

1. high risk of bleeding

\- Evidence of a recent history of bleeding in the last three months, hemorrhagic diathesis in the last three months, changes in coagulation tests (INR\> 1.5 or aPTT \> 2), pulmonary bronchiectasis, active cancer, active gastroduodenal ulcer, use of dual antiplatelet therapy.
2. Recent hemorrhagic stroke (1 month) or any history of previous hemorrhagic or lacunar stroke, if detected by occasional prior tomography, which is not part of the study protocol.
3. severe heart failure (NYHA class III and VI)
4. advanced stable kidney disease (estimated creatinine clearance \<15 ml per minute), defined as eTFG \<15 mL/min by 1.73 m2 calculated by the abbreviated formula Diet Modification in Kidney Disease (MDRD).
5. the use of dual antiplatelet therapy, anticoagulation, or other antithrombotic therapy
6. Continuous use of pentoxifylline or cilostazol
7. Cardiac conditions that may lead to heart failure, such as unstable angina, arrhythmias, acute myocardial infarction in the last three months
8. Non-cardiac conditions that may interfere with the ability to complete functional tests (e.g., chronic obstructive pulmonary disease, anemia, rheumatologic diseases)
9. Non-cardiovascular conditions are considered by the researcher as associated with a poor prognosis.

a. Active cancer with a life expectancy of fewer than six months b. Collagen limiting diseases c. Previous or scheduled surgeries that prevent functional evaluation d. Orthopedic diseases that hinder functional evaluation (j) Pregnancy. Women with the potential to bear children should be under contraceptive strategies and take a negative pregnancy test to be enrolled.

(k) Patients with COVID in the contagious phase (PCR+)

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No